1204221-60-2

Basic information

• Product Name: ethyl 2-(4-(2-chloro-5-bromobenzyl)phenoxy)acetate
• Synonyms: ethyl 2-(4-(2-chloro-5-bromobenzyl)phenoxy)acetate
• CAS NO: 1204221-60-2
• Molecular Weight: 383.669
• Mol File: 1204221-60-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: ethyl 2-(4-(2-chloro-5-bromobenzyl)phenoxy)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 2-(4-(2-chloro-5-bromobenzyl)phenoxy)acetate(1204221-60-2)
• EPA Substance Registry System: ethyl 2-(4-(2-chloro-5-bromobenzyl)phenoxy)acetate(1204221-60-2)

Safety Data

• Hazardous Substances Data: 1204221-60-2(Hazardous Substances Data)

Upstream product

• 108-95-2 phenol 
• 2555-49-9 phenoxyacetic acid ethyl ester 
• 864070-18-8 4-(5-bromo-2-chlorobenzyl)phenol 
• 105-36-2 ethyl bromoacetate 

Downstream Products

• 1204221-70-4 (3R,4S,5S,6R)-2-(4-chloro-3-(4-(2-cyclopropoxy(ethoxy-2,2-d2))benzyl)phenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol 
• 1204221-72-6 (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(2-cyclopropoxy(ethoxy-2,2-d2))benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 
• 1204221-64-6 4-bromo-1-chloro-2-(4-(2-(1-ethoxyethoxy)ethoxy-2,2-d2)-benzyl)benzene 
• 1204221-68-0 4-bromo-1-chloro-2-(4-(2-cyclopropoxy(ethoxy-2,2-d2))-benzyl)benzene 
• 1204221-66-8 4-bromo-1-chloro-2-(4-(2-(vinyloxy)ethoxy-2,2-d2)-benzyl)benzene 

Relevant articles and documents

A novel C - aryl glucoside SGLT2 inhibitor

The invention discloses a new C-aryl glycosidase SGLT2 (sodium glucose transporter type-2) inhibitor, relates to the field of medicines associated with diabetes, and in particular relates to a new C-aryl glycosidase derivative shown as the general formula (I), a preparation method thereof, compositions thereof, and use thereof in preparing hypoglycemic drugs. The C-aryl glucoside derivative has excellent effect of promoting urine discharge and in-vivo hypoglycemic activity, and compounds with equal or better in-vivo hypoglycemic activity than that of dapagliflozin are screened out, and can be used for the prevention or treatment of diabetes.

DEUTERATED BENZYLBENZENE DERIVATIVES AND METHODS OF USE

Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions that are affected by SGLT inhibition.